These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29580739)

  • 1. Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.
    Yuan J; Li B; Zhang N; Zhu H; Zhou L; Zhang L; Yang M
    Clin Lung Cancer; 2018 Jul; 19(4):e431-e438. PubMed ID: 29580739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
    Ariyasu R; Yanagitani N; Tadokoro K; Yamaguchi T; Uchibori K; Kitazono S; Fujita N; Katayama R; Nishio M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):517-525. PubMed ID: 32948919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
    Takeuchi S; Hase T; Shimizu S; Ando M; Hata A; Murakami H; Kawakami T; Nagase K; Yoshimura K; Fujiwara T; Tanimoto A; Nishiyama A; Arai S; Fukuda K; Katakami N; Takahashi T; Hasegawa Y; Ko TK; Ong ST; Yano S
    Cancer Sci; 2020 Feb; 111(2):561-570. PubMed ID: 31782583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
    Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
    Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.
    Lee JH; Lin YL; Hsu WH; Chen HY; Chang YC; Yu CJ; Shih JY; Lin CC; Chen KY; Ho CC; Laio WY; Yang PC; Yang JC
    J Thorac Oncol; 2014 Sep; 9(9):1385-92. PubMed ID: 25057939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer: An updated meta-analysis.
    Su W; Zhang X; Cai X; Peng M; Wang F; Wang Y
    Medicine (Baltimore); 2019 Mar; 98(10):e14568. PubMed ID: 30855441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
    Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma].
    Qian K; Zhang Y; Zhi X
    Zhongguo Fei Ai Za Zhi; 2017 Aug; 20(8):543-548. PubMed ID: 28855035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.
    Soh SX; Siddiqui FJ; Allen JC; Kim GW; Lee JC; Yatabe Y; Soda M; Mano H; Soo RA; Chin TM; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee JH; Yang JC; Zhao M; Zhou C; Lee JK; Lee SH; Lee JY; Ahn MJ; Tan TJ; Tan DS; Tan EH; Ong ST; Lim WT
    Oncotarget; 2017 Jun; 8(25):41474-41486. PubMed ID: 28467813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis.
    Ma JY; Yan HJ; Gu W
    J Cancer Res Ther; 2015; 11(2):397-402. PubMed ID: 26148607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
    Takeuchi S; Yoshimura K; Fujiwara T; Ando M; Shimizu S; Nagase K; Hasegawa Y; Takahashi T; Katakami N; Inoue A; Yano S
    J Med Invest; 2017; 64(3.4):321-325. PubMed ID: 28955007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs.
    Zhang N; Li Y; Zheng Y; Zhang L; Pan Y; Yu J; Yang M
    Lab Invest; 2019 Apr; 99(4):568-576. PubMed ID: 30552364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma.
    Wu SG; Liu YN; Yu CJ; Yang PC; Shih JY
    JAMA Oncol; 2016 Jun; 2(6):826-8. PubMed ID: 27077907
    [No Abstract]   [Full Text] [Related]  

  • 18. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.
    Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Makino T; Otsuka H; Sano GO; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
    Cancer Genomics Proteomics; 2016 11-12; 13(6):475-482. PubMed ID: 27807070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.
    Nie W; Tao X; Wei H; Chen WS; Li B
    Oncotarget; 2015 Sep; 6(28):25696-700. PubMed ID: 26325082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.